Cargando…
Serum Metallothioneins in Childhood Tumours—A Potential Prognostic Marker
Metallothioneins (MT) are low molecular weight, cysteine-rich proteins maintaining metal ions homeostasis. They play a role in carcinogenesis and may also cause chemoresistance. The aim of the study was to explore the importance of MT serum levels in children suffering from malignant tumours. This p...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Molecular Diversity Preservation International (MDPI)
2013
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3709780/ https://www.ncbi.nlm.nih.gov/pubmed/23743828 http://dx.doi.org/10.3390/ijms140612170 |
_version_ | 1782276801843691520 |
---|---|
author | Kruseova, Jarmila Hynek, David Adam, Vojtech Kizek, Rene Prusa, Richard Hrabeta, Jan Eckschlager, Tomas |
author_facet | Kruseova, Jarmila Hynek, David Adam, Vojtech Kizek, Rene Prusa, Richard Hrabeta, Jan Eckschlager, Tomas |
author_sort | Kruseova, Jarmila |
collection | PubMed |
description | Metallothioneins (MT) are low molecular weight, cysteine-rich proteins maintaining metal ions homeostasis. They play a role in carcinogenesis and may also cause chemoresistance. The aim of the study was to explore the importance of MT serum levels in children suffering from malignant tumours. This prospective study involves examination of 865 samples from 172 patients with malignant tumours treated from 2008 to 2011 at University Hospital Motol. MT serum levels were determined using differential pulse voltammetry–Brdicka reaction. Mean MT level was 2.7 ± 0.5 μM. There was no statistically significant difference between MT levels in different tumours. We also did not find any correlation between MT levels and response to therapy or clinical stages. However, we found a positive correlation between MT levels and age (p = 0.009) and a negative correlation with absolute lymphocyte number (p = 0.001). The fact that patients who had early disease recurrence had lower MT levels during the treatment (complete remission 2.67 vs. recurring 2.34, p = 0.001) seems to be important for clinical practice. Accordingly we believe that there is benefit in further studies of serum MT levels in tumours. |
format | Online Article Text |
id | pubmed-3709780 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2013 |
publisher | Molecular Diversity Preservation International (MDPI) |
record_format | MEDLINE/PubMed |
spelling | pubmed-37097802013-07-12 Serum Metallothioneins in Childhood Tumours—A Potential Prognostic Marker Kruseova, Jarmila Hynek, David Adam, Vojtech Kizek, Rene Prusa, Richard Hrabeta, Jan Eckschlager, Tomas Int J Mol Sci Article Metallothioneins (MT) are low molecular weight, cysteine-rich proteins maintaining metal ions homeostasis. They play a role in carcinogenesis and may also cause chemoresistance. The aim of the study was to explore the importance of MT serum levels in children suffering from malignant tumours. This prospective study involves examination of 865 samples from 172 patients with malignant tumours treated from 2008 to 2011 at University Hospital Motol. MT serum levels were determined using differential pulse voltammetry–Brdicka reaction. Mean MT level was 2.7 ± 0.5 μM. There was no statistically significant difference between MT levels in different tumours. We also did not find any correlation between MT levels and response to therapy or clinical stages. However, we found a positive correlation between MT levels and age (p = 0.009) and a negative correlation with absolute lymphocyte number (p = 0.001). The fact that patients who had early disease recurrence had lower MT levels during the treatment (complete remission 2.67 vs. recurring 2.34, p = 0.001) seems to be important for clinical practice. Accordingly we believe that there is benefit in further studies of serum MT levels in tumours. Molecular Diversity Preservation International (MDPI) 2013-06-06 /pmc/articles/PMC3709780/ /pubmed/23743828 http://dx.doi.org/10.3390/ijms140612170 Text en © 2013 by the authors; licensee MDPI, Basel, Switzerland This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution license (http://creativecommons.org/licenses/by/3.0/). |
spellingShingle | Article Kruseova, Jarmila Hynek, David Adam, Vojtech Kizek, Rene Prusa, Richard Hrabeta, Jan Eckschlager, Tomas Serum Metallothioneins in Childhood Tumours—A Potential Prognostic Marker |
title | Serum Metallothioneins in Childhood Tumours—A Potential Prognostic Marker |
title_full | Serum Metallothioneins in Childhood Tumours—A Potential Prognostic Marker |
title_fullStr | Serum Metallothioneins in Childhood Tumours—A Potential Prognostic Marker |
title_full_unstemmed | Serum Metallothioneins in Childhood Tumours—A Potential Prognostic Marker |
title_short | Serum Metallothioneins in Childhood Tumours—A Potential Prognostic Marker |
title_sort | serum metallothioneins in childhood tumours—a potential prognostic marker |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3709780/ https://www.ncbi.nlm.nih.gov/pubmed/23743828 http://dx.doi.org/10.3390/ijms140612170 |
work_keys_str_mv | AT kruseovajarmila serummetallothioneinsinchildhoodtumoursapotentialprognosticmarker AT hynekdavid serummetallothioneinsinchildhoodtumoursapotentialprognosticmarker AT adamvojtech serummetallothioneinsinchildhoodtumoursapotentialprognosticmarker AT kizekrene serummetallothioneinsinchildhoodtumoursapotentialprognosticmarker AT prusarichard serummetallothioneinsinchildhoodtumoursapotentialprognosticmarker AT hrabetajan serummetallothioneinsinchildhoodtumoursapotentialprognosticmarker AT eckschlagertomas serummetallothioneinsinchildhoodtumoursapotentialprognosticmarker |